Injexate Autoinjektor (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor needed for DNA synthesis. By limiting nucleotide formation, it suppresses the proliferation of rapidly dividing cells, including immune cells that drive inflammation and malignant cells in cancer.

The dose of Injexate Autoinjector is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment response. Healthcare providers determine the appropriate amount and frequency, and patients should follow the prescribed regimen exactly.

Methotrexate is classified as Pregnancy Category X because it is teratogenic and can cause fetal malformations. It is contraindicated during pregnancy and should be stopped well before conception. Breastfeeding is not recommended, as methotrexate is excreted in milk and may harm the infant.

To order Injexate Autoinjector, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Injexate (methotrexate) is a conventional synthetic DMARD, whereas biologic agents such as adalimumab target specific cytokines. Methotrexate is generally less expensive and can be combined with biologics for synergistic effect, but biologics may have a faster onset of action and a different safety profile, especially regarding infection risk.

Injexate Autoinjector should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the device. If temporary exposure to higher temperatures occurs, ensure the product is used within the manufacturer’s stability window, and always keep it in the original packaging to maintain sterility.

Injexate is delivered by subcutaneous injection using a pre‑filled autoinjector. The patient or healthcare professional selects the injection site (typically the abdomen or thigh), cleans the area with an alcohol swab, activates the autoinjector, and holds it in place for the recommended time before disposal in a sharps container.

Serious risks associated with methotrexate include severe liver toxicity, pulmonary fibrosis, and bone‑marrow suppression leading to pancytopenia. Patients should be educated to report persistent cough, unexplained bruising, jaundice, or signs of infection promptly, as these may indicate life‑threatening complications.

Injexate is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, and patients with known hypersensitivity to methotrexate or any component of the formulation. Caution is also advised for patients with active infections, uncontrolled immunodeficiency, or a history of pulmonary disease.